Description
ACVR2B (ACE-031) 10 mg Nouveaux — ACE-031 (ACVR2B) from Nouveaux at 10 mg. Recombinant soluble activin-receptor fusion protein acting as myostatin decoy. Clinical trial safety signal (epistaxis/vascular fragility) — research-only.
Key Benefits
- Soluble activin receptor IIB decoy — neutralises myostatin + activin A
- Direct myostatin pathway inhibition
- SubQ dosing, weekly schedule
- Investigational only — not commercially approved
- Research interest in muscle-wasting protocols
- Each unit dosed at 10 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 1 mg/kg SubQ every 2 weeks in early clinical trials. Scaled-down research protocols: 100–200 mcg/kg weekly. Investigational-only status.
How It Works
Engineered soluble activin receptor IIB fused to IgG Fc domain. Acts as a decoy receptor, trapping myostatin and activin A before they can signal through native receptors. Upstream of follistatin’s mechanism.
Pharmacokinetics
Plasma half-life approximately 10–12 days (Fc-fusion extends half-life). Weekly or bi-weekly dosing. Research-grade reconstitution fridge-stable 4–6 weeks.
Potential Side Effects
Phase-1 trials halted due to nosebleeds and gum-bleeding — attributed to off-target effects on BMP-signalling pathways that include vascular-maintenance. Informational use only.
Cycle & Stacking Guide
Research-only. If used, short 2–4 week protocols with close monitoring. Not recommended for routine supplementation.
Manufacturer Notes
Nouveaux focuses on high-concentration injectable AAS and peptides. Standard batch QC documentation; scannable authenticity verifiers on each vial.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.